Germany’s federal parliament passed a cost-saving drug policy that doubles mandatory manufacturer rebates on many brand-name prescriptions from 7% to 15.5%. The legislation also raises discount levels for patented vaccines and includes price-freeze provisions for vaccines used for immunizations from 2027 through 2030. Drugmakers and trade groups criticized the bill as potentially harmful to the industry, while policy proponents framed it as controlling statutory health insurance spending. For biotech companies with commercial exposure in Germany, the change affects pricing strategy and could tighten how value propositions are documented for market access and rebate contract negotiations.